Eli Lilly expects to launch the drug for OSA at the beginning ... The index is used to evaluate the severity of obstructive sleep apnea and the effectiveness of treatments for the condition. Disease ...

The Food and Drug Administration approved Eli Lilly’s weight-loss drug Zepbound on Dec. 27 to treat sleep apnea, a common but ...

Key Takeaways Shares of ResMed and Inspire Medical Systems fell after the FDA approved Eli Lilly's weight-loss drug Zepbound ...

The FDA has expanded the approval of Eli Lilly’s obesity medication Zepbound to include treating moderate to severe obstructive sleep apnea for people with obesity.

The first medication for obstructive sleep apnea has been approved by the US Food and Drug Administration (FDA).

The FDA has approved Lilly's Zepbound, a glp-1 agonist, for the treatment of sleep apnea, which affects 25 million Americans ...

The FDA on Friday approved Eli Lilly's weight-loss drug Zepbound as a treatment for moderate-to-severe sleep apnea and ...

Dec 20 (Reuters) - The U.S. Food and Drug Administration on Friday approved Eli Lilly's (LLY.N), opens new tab weight-loss treatment, Zepbound, for obstructive sleep apnea, making it the first drug ...

The FDA has cleared Eli Lilly’s obesity drug Zepbound as the first treatment for obstructive sleep apnea in the U.S.

Zepbound, a drug approved by the FDA, has been shown to reduce the severity of obstructive sleep apnea in obese adults, ...

The US Food and Drug Administration has approved Zepbound (tirzepatide) as the first prescription medication for the treatment of obstructive sleep apnea (OSA).

After plugging billions into its manufacturing network to meet rampant demand for Mounjaro and Zepbound, Eli Lilly is looking ...